Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation
暂无分享,去创建一个
Caroline Dive | Andrew Pierce | Julia M. Francis | Anthony D Whetton | Jaleel A. Miyan | T. Dexter | A. Whetton | C. Dive | A. Pierce | P. J. Owen-Lynch | E. Spooncer | Elaine Spooncer | Sarah Wooley | Julia M Francis | Jaleel Miyan | P Jane Owen-Lynch | T Michael Dexter | Sarah Wooley
[1] T. Dexter,et al. Self-renewal and differentiation of interleukin-3-dependent multipotent stem cells are modulated by stromal cells and serum factors. , 1986, Differentiation; research in biological diversity.
[2] D. Pinkel,et al. Retention of wild‐type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation , 1998, The EMBO journal.
[3] M. Bar‐eli,et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. , 1991, The Journal of clinical investigation.
[4] A. Gotoh,et al. The function of BCR/ABL and related proto‐oncogenes , 1997, Current opinion in hematology.
[5] D. Huhn,et al. Analysis of the p53 and MDM‐2 gene in acute myeloid leukemia , 1996, European journal of haematology.
[6] Susan M. Watanabe,et al. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity , 1984, Cell.
[7] K. Ishizaki,et al. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. , 1992, Cancer research.
[8] O. Witte,et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.
[9] T. Dexter,et al. Expression of the GM-CSF gene after retroviral transfer in hematopoietic stem cell lines induces synchronous granulocyte-macrophage differentiation , 1991, Cell.
[10] B. Pedersen. FUNCTIONAL AND BIOCHEMICAL PHENOTYPE IN RELATION TO CELLULAR AGE OF DIFFERENTIATED NEUTROPHILS IN CHRONIC MYELOID LEUKAEMIA , 1982, British journal of haematology.
[11] G. Daley,et al. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[12] U. Knippschild,et al. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. , 1996, The EMBO journal.
[13] H. Nakshatri,et al. Regulation of the c-jun Gene in p210 BCR-ABL Transformed Cells Corresponds With Activity of JNK, the c-jun N-Terminal Kinase , 1998 .
[14] G. Jenster,et al. Acute leukaemia in bcr/abl transgenic mice , 1990, Nature.
[15] S. Misawa,et al. Chromosome 17 abnormalities and inactivation of the p53 gene in chronic myeloid leukemia and their prognostic significance. , 1995, Leukemia & lymphoma.
[16] T. Hambuch,et al. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[17] R. Jaenisch,et al. Regulation of ES cell differentiation by functional and conformational modulation of p53 , 1997, The EMBO journal.
[18] D. Cortez,et al. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. , 1998, Genes & development.
[19] C. Eaves,et al. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[20] T. Soussi,et al. A functional analysis of p53 during early development of xenopus laevis , 1997, Oncogene.
[21] K. Ishizaki,et al. Hemizygous expression of the wild‐type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukaemia , 1995, British journal of haematology.
[22] L. Wiedemann,et al. A temperature sensitive p210 BCR‐ABL mutant defines the primary consequences of BCR‐ABL tyrosine kinase expression in growth factor dependent cells. , 1994, The EMBO journal.
[23] C. Figdor,et al. Competition between lymphocyte function‐associated antigen 1 (CD11a/CD18) and Mac‐1 (CD11b/CD18) for binding to intercellular adhesion molecule‐1 (CD54) , 1996, Journal of leukocyte biology.
[24] G. Blandino,et al. Interference with p53 protein inhibits hematopoietic and muscle differentiation , 1996, The Journal of cell biology.
[25] E. Shaulian,et al. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.
[26] Y. Yazaki,et al. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. , 2000, Blood.
[27] S. Benchimol,et al. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[28] T. Dexter,et al. p210 Bcr–Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia , 1998, Oncogene.
[29] C. Verfaillie. Biology of chronic myelogenous leukemia. , 1998, Hematology/oncology clinics of North America.
[30] M. Pincus,et al. MEKK1/JNK signaling stabilizes and activates p53. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[31] P. Chumakov,et al. Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells. , 1997, Oncology research.
[32] G. Daley,et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.
[33] S. Powell,et al. Inactivation of p53 results in high rates of homologous recombination , 1997, Oncogene.
[34] M. Moore,et al. Responsiveness of human granulocytic leukemic cells to colony-stimulating factor. , 1974, Blood.
[35] B. Calabretta,et al. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[36] N. Rosenberg,et al. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[37] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[38] G. Krystal,et al. BCR – ABL accelerates C2-ceramide-induced apoptosis , 1998, Oncogene.
[39] V. Adler,et al. JNK targets p53 ubiquitination and degradation in nonstressed cells. , 1998, Genes & development.
[40] M. D. de Bruijn,et al. Markers of mouse macrophage development detected by monoclonal antibodies. , 1994, Journal of immunological methods.
[41] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[42] O. Witte,et al. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. , 1992, Science.